Effect of Tesofensine on Weight Reduction in Patients With Obesity.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-09-30

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose:

To evaluate the efficacy on weight reduction, metabolic parameters and safety of tesofensine versus placebo in obese patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Long Term Safety of Tesofensine in Patients With Obesity

NCT00481104

Obesity

COMPLETED PHASE2

Sodium Tungstate in Obesity

NCT00555074

Obesity

COMPLETED PHASE2

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

NCT05147415

Hypothalamic Obesity

WITHDRAWN PHASE2

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

NCT07036601

Overweight or Obese

RECRUITING PHASE2

Efficacy and Safety of THR-4109 in Obese Subjects

NCT00485017

Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tesofensine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obese patients with 30 kg/m² ≤ BMI ≤ 40 kg/m²
* Males and females 18 to 65 years of age, extremes included
* Patients continuously receiving diet therapy as well as instructions on exercise at least for 2 weeks run-in, who during the run-in before randomization do not gain weight (\< 2 kg)
* Females of childbearing potential must be non-pregnant and use safe contraceptive methods (the pill, IUD or surgically sterilized)
* Patients should be able to comply with study procedures
* Smoking habits should have been stable for at least 2 months
* Patients giving written informed consent

Exclusion Criteria

* Use of prescription medication as listed
* Positive serum pregnancy test for women of childbearing potential
* Pregnant or lactating women, or women who are planning to become pregnant within the next 8 months
* Patients with specific diseases interfering with their metabolism e.g. untreated myxoedema, Cushing's syndrome, Type 1 diabetes mellitus, significant neurological or psychiatric illness such as epilepsy, schizophrenia, depression, eating disorders such as bulimia.
* Patients currently (within the past 2 months) known to abuse or to be dependent on any drug, including alcohol (weekly consumption \> 21 units of alcohol (men) or \>14 units of alcohol (women))
* Hepatic or renal dysfunction (ASAT and/or ALAT \> 2 x ULN and creatinine clearance \< 30 mL/min estimated by central laboratory using Cockcroft and Gault formula, respectively)
* Known untreated hypercholesterolaemia (\> 7 mmol/l). Patients with well regulated cholesterol using drugs for hypercholesterolaemia are allowed inclusion
* Known untreated hypertriglyceridaemia (\> 3 mmol/l). Patients with well regulated triglyceride levels using drugs for hypertriglyceridaemia are allowed inclusion
* Drug treated thyroid diseases (well substituted hypothyroidism is allowed)
* Patients who suffer from hyperthyroid disease are not allowed in the study, even though they may be well treated by drugs
* Patients, who have recently diagnosed, not yet stable hypothyroid disease are not allowed in the study
* Patients who suffer from longstanding stable hypothyroid disease, well treated substitution are allowed to be included including hypothyroidism as a sequelae to definitive treatment of hyperthyroidism by surgery or radioactive iodine
* Malabsorptive intestinal disorders that can be assumed to affect the absorption of tesofensine
* Special diets (e.g., vegetarian, Atkins)
* Patients planning major changes in physical activity during the study to an extent that may interfere with the study outcome, as judged by the investigator
* Weight change of \> 3 kg within 2 months prior to screening
* Mental or psychiatric disorder based on medical history only
* Surgically treated obesity
* Patients with systemic infections or inflammatory diseases
* History or presence of significant cardiovascular disease such as heart failure, ischemic heart disease, stroke, transient ischemic attacks
* Significant abnormalities on the ECG. according to the investigators opinion. Additional exclusionary ECG values: QTcB \> 480 milliseconds (ms), PR interval \> 240 ms, QRS interval \> 120 ms
* Hypotension (i.e. supine systolic BP \< 90 mm Hg) and/or symptomatic orthostatic hypotension (clinical symptoms of orthostatic hypotension associated with a decline ≥ 20 mm Hg in systolic BP at one minute after standing compared with the previous supine systolic BP obtained after 5 minutes of quiet rest) at screening visit
* Uncontrolled hypertension (i.e. sitting diastolic BP ≥ 95 mm Hg and sitting systolic BP ≥ 155 mm Hg) despite treatment for \> 4 weeks prior to the screening visit as well as HR\>90 bpm
* Known HIV infection (no tests required)
* Serologic evidence of active hepatitis B and/or C
* History of cancer within the past 5 years, excluding treated basal cell carcinoma
* Clinically significant or potentially disabling eye disorder, including uncontrolled glaucoma
* Current treatment with medication with known ocular toxicity such as chloroquine and hydroxychloroquine is prohibited
* Patients previously treated with tesofensine
* Patients treated with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study drug

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No